CELZ seeks shareholder approval to boost authorized shares to 100M and greenlight 5.58M warrant exercise

summarizeSummary

CELZ shareholders will vote August 28 on increasing authorized shares from 25M to 100M and approving exercise of 5.58M warrants at $1.60. The warrant exercise alone would more than double the outstanding share count, and the broader authorization enables massive future dilution for a cash-strapped, zero-revenue company.

check_boxKey Events · Corporate Governance and Compliance · CELZ

• Authorized Share Increase to 100M

  Proposal to amend Articles of Incorporation to increase authorized common shares from 25 million to 100 million. As of June 30, 2026, 4.74M shares outstanding and 10.63M warrants/options leave only ~9.65M shares available, insufficient to cover existing derivative securities.

• 5.58M Warrant Exercise Approval

  Shareholders asked to approve exercise of 5,580,680 Investor Warrants at $1.60 per share, issued in a June 2026 private placement. Exercise would more than double the outstanding share count, causing significant dilution.

• Special Meeting Set for August 28, 2026

  Record date June 30, 2026. Failure to approve the warrant exercise requires the company to hold additional stockholder meetings every 60 days, incurring substantial costs.

• Cash-Strapped Biotech with Zero Revenue

  Company reported zero revenue and a $1.48M cash decrease in Q1 2026. Recently raised $4.5M via warrant inducement, but ongoing cash burn and lack of revenue heighten the urgency of these proposals.

auto_awesomeAnalysis · CELZ · Life Sciences

Creative Medical Technology Holdings is asking shareholders to approve a quadrupling of authorized shares to 100 million and the exercise of 5.58 million warrants at $1.60 per share. With only 4.74 million shares outstanding and 10.63 million warrants/options already in play, the current 25 million share cap leaves just 9.65 million shares available — insufficient to cover existing derivative securities. The warrant exercise alone would dilute existing holders by over 100%, and the broader share increase opens the door to significant future dilution. This vote is critical: failure to approve the warrant exercise forces the company to hold costly special meetings every 60 days, draining cash from a zero-revenue biotech that just raised $4.5 million in a distressed warrant inducement deal.